Today we are emerging from stealth and announcing that we've raised $3M in pre-seed funding to further our patient-outcome driven mission of uniting the giant leaps we've made in psychedelic medicine with deeply personal therapeutic transformations to create lasting transformation within patients. Our pre-seed round was led Greycroft with participation from an incredible group of other seasoned, mission-oriented investors including Looking Glass, Max Ventures, and more.

What is Innerwell? We're a revolutionary psychedelic therapy platform with an emphasis on therapy. We’re bringing a true ketamine-assisted psychotherapy experience virtual to help patients with anxiety and depression - and that’s just the beginning, as we’re already working towards expanding the gold standard model of psychedelic therapy for at-home and in-person treatment aided by groundbreaking medicine like psilocybin and MDMA.

We are building Innerwell to help the 65 million Americans suffering from mental illness each year. We are creating a collaborative environment in which psychiatrists and therapists can work side-by-side to apply the irreplaceable human lens to patients’ therapeutic explorations, and we are building the infrastructure to capture key behavioral health measurements that allow us to optimize for patient outcomes.

The need for integrated and accessible mental health care is only increasing due to the Covid-19 pandemic. We believe that each approach to mental health care must be highly personalized for the individual, and there is a growing body of evidence and research showing that the combination of psychedelic medicine and psychotherapy is especially beneficial for those suffering from ongoing mental health conditions such as anxiety and depression.

Here's what sets our patient experience apart:

• Licensed clinicians with specialized training in psychedelic-assisted therapy, starting with Ketamine
• Building therapeutic relationships to help patients experience psychedelic therapy in a safe, supervised environment
• Personalized digital care to support patients before, during, and after their experience
• Measurement and data focused approach to improving patient outcomes

Starting today, we are recruiting licensed clinicians and training them in partnership with the industry leaders at Fluence. In addition to competitive pay, our founding class of clinical and therapist thought leaders will receive stock options as our partners in building the future of psychedelics.

Are you a licensed therapist, counselor, social worker, psychologist, or prescribing clinician looking to get involved? Learn More